Materials and Methods

Reagents
Tazobactam, meropenem, and sodium piperacillin were from Molekula. Avibactam was a gift from AstraZeneca. Unless otherwise stated, other reagents were from SigmaAldrich.
Mutagenesis
The Y58C SPM-1 and F151C SPM-1 variants were generated using the wildtype (wt) pOPINF SPM-1 plasmid. [1] The desired point mutations were achieved employing the QuikChange site directed mutagenesis kit (Stratagene) using the following primers: Recombinant di-Zn(II)-SPM-1 proteins were produced in E. coli BL21(DE3) pLysS cells using 2TY medium supplemented with 50 μg/mL ampicillin and 34 μg/mL chloramphenicol.
Cells were grown at 37 ºC until they reached OD 600 = 0.6-0.8; the temperature was then reduced to 30 ºC for 6 h. Cells were harvested by centrifugation (10 min, 10g), then resuspended in 50 mL lysis buffer supplemented with DNaseI, lysozyme and EDTA-free protease-inhibitors. The cells were then further lysed by sonication (2 x 7 min); cell debris was then removed by centrifugation (20 g, 30 min). The cell lysates were then loaded onto a 5 mL HisTrap HP column (GE Healthcare Life Sciences, Little Chalfont, UK), with 50 mM Tris pH 7.5, 500 mM NaCl, containing 20 mM imidazole, then eluted with an imidazole gradient (up to 500 mM imidazole). Fractions containing di-Zn(II)-SPM-1 were further purified using a Superdex S200 column (300 mL) equilibrated with 20 mM Tris, pH 7.5, 200
mM NaCl. Eluted SPM-1 fractions were incubated overnight at 4 °C with 3C protease (1:100 w/w) and then purified using a 5 mL HisTrap HP column to give the untagged protein. The purity of the resulting fractions was assessed as > 90% (by SDS-PAGE). Fractions containing purified protein were concentrated by centrifugal ultra-filtration (10 kDa cut-off membrane).
The concentrations of the purified proteins were determined using a ND-1000 NanoDrop spectrophotometer, as previously reported.
Fluorine Labeling
SPM-1 variants (Y58C and F151C) were incubated on ice with tris-(2-carboxyethyl)phosphine (TCEP, final concentration 2 mM) in 50 mM Tris buffer, pH 7.5, for 30 min. The samples were buffer exchanged into phosphate buffer (50 mM, pH 7.0, 200 mM NaCl) using a PD-10 desalting column (GE Healthcare). A concentrated stock of 100 mM 3-bromo-1,1,1-trifluoroacetone (BTFA) reagent in phosphate buffer was prepared freshly prior to the reaction. SPM-1 variant samples were treated with 35-fold equivalent of 3-bromo-1,1,1-trifluoroacetone for 10 min at room temperature, prior to buffer exchange into Tris buffer (50 mM, pH 7.5, 200 mM NaCl) using a PD-10 desalting column (GE Healthcare).
[2]
Apo-SPM-1 Production
Apo-SPM-1 proteins were produced by EDTA treatment of the di-Zn(II)-SPM-1. The di-Zn(II)-SPM-1 variants were incubated with 1,000-equivalents of EDTA at 4 ºC overnight.
The treated proteins were purified using a Superdex S200 column (300 mL) equilibrated with 20 mM Tris pH 7.5, 200 mM NaCl. Fractions containing purified protein were concentrated by centrifugal ultrafiltration (10 kDa cutoffs). The purity of the resulting fractions was ascertained to be > 90% by SDS-PAGE. Concentrations of the purified proteins were determined using a ND-1000 NanoDrop spectrophotometer. Removal of the metal was confirmed by non-denaturing mass spectrometry and activity analyses.
Protein Electrospray Ionization Mass Spectrometry
Low resolution positive ion electrospray mass spectra were recorded using an LCT Premier XE ionization (Micromass ® ) mass spectrometer interfaced with a Acquity ™ Ultra
Performance liquid chromatography (UPLC) system using a Acquity ™ UPLCR BEH300 C18 
In-Solution Trypsin Digestion
All reagents were prepared in Tris buffer (100 mM, pH 7.8). Samples (< 500 μg) were dried in a Vacufuge® vacuum concentrator (Eppendorf) connected to an external diaphragm pump and then resuspended in 6 M urea (100 μL). Disulfides were reduced at room temperature 
MALDI-ToF-MS and MS/MS Studies
Matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDIToF-MS) and MS/MS analyses were performed using a Bruker Daltonics Ultraflex™ MALDI-ToF/ToF machine, using flexControl™ 3.0 software. Spectra were recorded in the positive ion reflectron mode, typically with 32-38 % laser energy. Calibration was performed on each day prior to the measurements using Peptide Calibration Standard II (Bruker Daltonics). Data were processed using Bruker Daltonics flexAnalysis™ 3.0 software and assigned manually. For MALDI measurements, the sample (1 μL) was mixed with 2,5-dihydroxybenzoic acid (4 μL, DHB, 20 mg/mL in 50 % CH 3 CN/0.1 % CF 3 COOH) matrix and this sample-matrix mixture spotted (2 μL) onto a 24 x 16 MTP AnchorChip™ 384 ToF MALDI target and allowed to air-dry before analysis.
Circular Dichroism (CD) Experiments
CD measurements were carried out using a Chirascan CD spectrometer (Applied Photophysics) equipped with a Peltier temperature-controlled cell holder. Experiments were performed at 23 °C in a 0.1 cm path length cuvette using 0.2 mg/mL protein in 10 mM sodium phosphate buffer (pH 8.0) supplemented with 50 mM ZnSO 4 . Data were recorded from 260 to 185 nm at 0.5 nm intervals; each data point was averaged for 1 s. Spectra were baseline corrected and smoothed using the Savitzky-Golay filter. Data recorded in the 190-240 nm range were analyzed using DichroWeb; the CDSSTR deconvolution method was used to estimate secondary structural content using reference set 4. To minimize the effects of differences in protein concentration, the data were normalized at 207 nm.
[4]
Crystallization Conditions
SPM-1 Y58C (20 mg/mL) was crystallized using sitting-drop vapor diffusion in 24-well Cryschem plates (Hampton Research). Protein (2 µL) was mixed with crystallization reagent (0.1 M mixture of HEPES and MOPS, pH 7.5, 0.03 M NaF, 0.03 M NaI, 0.03 M NaB, 12% PEG3350, 12% PEG1000, 12% 2-methyl-2,4-pentanediol) and equilibrated against 500 µL. Crystals grew to maximum size in 3 days and were looped directly from the drop and flash-frozen in liquid nitrogen. Diffraction data were collected at 100 K on beamline I24 (Diamond Light Source, Didcot, UK). The dataset was indexed and integrated using XDS [5] and scaled using Aimless in CCP4. [6] Data were cut at 1.75 Å as completeness dropped significantly at higher resolutions.
Phases were determined using molecular replacement in Phaser [7] with 4BP0 [2] as the search model (with Y58 mutated to a cysteine). The structure was refined and modelled using Phenix [8] and Coot, [9] respectively. After several rounds of refinement residue 58 was modelled as a cysteine into clearly defined electron density, before undergoing a final round of refinement and model building. Structure validation was assisted by Molprobity [10] and Phenix. Data collection and refinement statistics are given in Table S1 .
Steady-State Kinetics
Hydrolysis of meropenem was monitored at 25 C in 50 mM HEPES buffer (pH 7.2) supplemented with 1 µg/mL BSA, 1 mM ZnSO 4 and 0.01% Triton X-100. Analyses were carried out in triplicate (n≥3); the absorbance values were read using a BMG Labtech Pherastar FS plate reader at 300 nm. Extinction coefficients were determined by plotting the absorbance units against decreasing concentrations of the substrate. Kinetic constants (K M and k cat ) were obtained by determining the initial rate of the reaction at different substrate concentrations. The concentration-dependence of the initial rate was fitted and analyzed using GraphPad Prism 5.01 software to generate Michaelis-Menten curves. [11] Synthesis ML302 and ML302F were synthesized as reported by Brem et al. [12] The isoquinoline derivative (1) was synthesized as reported by van Berkel et al. [11] Production of Hydrolyzed β-Lactams β-Lactamase mediated hydrolysis was used to produce hydrolyzed meropenem and piperacillin. Incubation of 5 equivalents of piperacillin and meropenem with Bacillus cereus m569/H/9 (BcII) produced (5R)-penicilloic acid (PA) [and some (5S)-PA] and hydrolyzed meropenem, respectively. BcII was removed from the reaction mixture using PD-10 columns.
Subsequent epimerisation of (5R)-to (5S)-PA was performed under neutral conditions, nonenzymatically, at 4 o C, for an overnight. The hydrolyzed products were obtained via spin filtration using 10 kDa Centricon concentrators. The reaction and the purity of hydrolyzed β-lactams were assessed by NMR analyses. BcII was produced and purified as described by van
Berkel et al. [11] 
NMR Experiments
Spectra were recorded using a Bruker AVIII 600 with BB-19 F/ 1 H Prodigy N 2 cryoprobe operating at 298 K using 5 mm diameter NMR tubes (Norell). 
F-NMR Experiments
wLOGSY NMR Experiments
For water-Ligand Observed Gradient SpectroscopY (wLOGSY) analyses, [14] Fig. S1 . Views from MBL crystal structures highlighting potentially mobile regions. Views from structures of (A) IMP-1 (a di-Zn(II) binding B1 MBL, PDB ID:
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1JJT) [15] and (B) CphA (a mono-Zn(II) binding B2 MBL, PDB ID: 1X8I) [16] [3] The sites of labeling, F151 and Y58, are highlighted in green. Selected active site residues are shown as sticks in the highlighted circle. Zn1 is coordinated by 3 His residues, H116, H118, and H196, and Zn2 is coordinated by D120, H263, and C221. The figure was created using PyMOL. [18] The figure was created using PyMOL. The obtained crystal structure shows that Y58C SPM-1 has the conserved αββα MBL fold. [19] . [20] Hydrolyzed meropenem binds to the active site of New Delhi MBL-1 (NDM-1), a B1 subfamily MBL, in close proximity to the L3 loop. Supplementary Tables   Table S1. Data collection and refinement statistics. and slow hydrolysis were monitored (CPMG). [22]  Hydrolyzed products do not appear to bind to SPM-1 (wLOGSY). [22]  Addition of intact avibactam after 24 h led to shifting the equilibrium back to the avibactam.Y58C* SPM-1 complex peak. K D values were fitted using the following equation: [2] Δδ inhibitors undergo hydrolysis to multiple products. [23] 
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